Linde Valuation

Is 0M2B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0M2B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0M2B (€435.36) is trading above our estimate of fair value (€333.39)

Significantly Below Fair Value: 0M2B is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0M2B?

Key metric: As 0M2B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0M2B. This is calculated by dividing 0M2B's market cap by their current earnings.
What is 0M2B's PE Ratio?
PE Ratio34.1x
EarningsUS$6.38b
Market CapUS$217.41b

Price to Earnings Ratio vs Peers

How does 0M2B's PE Ratio compare to its peers?

The above table shows the PE ratio for 0M2B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.4x
RIO Rio Tinto Group
9.4x0.7%UK£83.8b
ANTO Antofagasta
27.2x18.5%UK£16.4b
AI L'Air Liquide
29.7x11.1%€90.1b
APD Air Products and Chemicals
19.3x1.5%US$74.4b
0M2B Linde
34.1x9.4%€217.4b

Price-To-Earnings vs Peers: 0M2B is expensive based on its Price-To-Earnings Ratio (34.1x) compared to the peer average (21.4x).


Price to Earnings Ratio vs Industry

How does 0M2B's PE Ratio compare vs other companies in the European Chemicals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0M2B 34.1xIndustry Avg. 17.3xNo. of Companies13PE01224364860+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0M2B is expensive based on its Price-To-Earnings Ratio (34.1x) compared to the European Chemicals industry average (17.2x).


Price to Earnings Ratio vs Fair Ratio

What is 0M2B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0M2B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio34.1x
Fair PE Ratio22.8x

Price-To-Earnings vs Fair Ratio: 0M2B is expensive based on its Price-To-Earnings Ratio (34.1x) compared to the estimated Fair Price-To-Earnings Ratio (22.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0M2B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€435.36
€474.36
+9.0%
7.9%€528.17€365.87n/a25
Nov ’25€421.60
€455.10
+7.9%
7.8%€507.54€351.59n/a25
Oct ’25€429.80
€438.41
+2.0%
7.8%€496.87€344.20n/a25
Sep ’25€429.20
€438.32
+2.1%
7.3%€494.84€342.79n/a25
Aug ’25€421.15
€434.70
+3.2%
7.2%€495.61€349.68n/a25
Jul ’25€401.60
€441.81
+10.0%
7.3%€504.58€356.01n/a25
Jun ’25€394.60
€435.27
+10.3%
7.2%€499.99€352.77n/a25
May ’25€413.00
€441.47
+6.9%
8.7%€504.47€324.17n/a25
Apr ’25€430.31
€434.52
+1.0%
8.7%€488.78€323.06n/a25
Mar ’25€414.96
€419.79
+1.2%
7.1%€463.70€321.04n/a25
Feb ’25€375.45
€405.09
+7.9%
6.8%€441.60€319.24n/a25
Jan ’25€370.17
€393.00
+6.2%
6.2%€434.78€314.31n/a26
Dec ’24€379.09
€392.64
+3.6%
5.5%€441.02€318.82n/a26
Nov ’24€363.41
€396.37
+9.1%
5.4%€423.86€326.84€421.6028
Oct ’24€354.62
€390.59
+10.1%
6.0%€421.16€317.27€429.8028
Sep ’24€358.32
€383.68
+7.1%
6.0%€412.47€310.73€429.2028
Aug ’24€356.59
€379.00
+6.3%
5.8%€409.23€308.29€421.1528
Jul ’24€350.13
€370.27
+5.8%
5.0%€397.15€313.10€401.6028
Jun ’24€331.68
€371.59
+12.0%
4.9%€399.64€315.07€394.6027
May ’24€332.31
€358.33
+7.8%
4.4%€390.23€331.24€413.0026
Apr ’24€323.43
€347.56
+7.5%
4.5%€379.82€308.84€430.3124
Mar ’24€325.04
€352.69
+8.5%
4.2%€392.04€314.20€414.9623
Feb ’24€302.65
€336.05
+11.0%
4.5%€371.05€309.21€375.4523
Jan ’24€305.58
€337.01
+10.3%
7.3%€379.25€245.28€370.1722
Dec ’23€319.21
€337.24
+5.6%
6.9%€367.00€251.11€379.0922
Nov ’23€301.39
€349.75
+16.0%
7.4%€391.40€260.94€363.4122

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies